December 9, 2022
Lilly Calls it quits
Ypsomed announced that Lilly terminated their joint US insulin pump project. Not sure how many partners Lilly has worked with on this ill-fated crazy effort to enter the insulin pump market but hopefully this is the last one. We’d like to say that the company realized it was crazy to compete with Insulet, Tandem and Medtronic. That it was foolish to believe they could make money starting from ground zero. That if they really wanted to be in the pump business why not buy their way in.
No, we suspect this decision had more to do with the . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
